Pulmorenal Sendromlar Anca ile İlişkili Vaskülitler
Özet
Bu makale, Granülomatöz Polianjit (GPA), Mikroskopik Polianjit (MPA) ve Eozinofilik Granülomatöz Polianjit (EGPA) hastalıklarını içeren Antinötrofil Sitoplazmik Otoantikor (ANCA) ilişkili vaskülitleri (AAV) kapsamlı bir şekilde incelemektedir. Küçük boyutlu damarları etkileyen bu bağışıklık sistemi kaynaklı karmaşık hastalıklar; böbrekler, akciğerler, cilt ve kulak-burun-boğaz gibi hayati organlarda fokal nekroz ve nekrotizan vaskülit gibi ciddi hasarlara yol açar. Genellikle halsizlik, ateş ve kilo kaybı gibi özgül olmayan belirtilerle başlayan hastalıklar, tanıda gecikildiğinde geri dönüşü olmayan organ disfonksiyonlarına veya ölüme neden olabilir. Tanı sürecinde ANCA testleri, doku biyopsileri ve bilgisayarlı tomografi gibi görüntüleme yöntemleri kritik rol oynar. Tedavi yönetimi, hastalığın şiddetine göre belirlenen indüksiyon ve idame olmak üzere iki temel fazdan oluşur. Yaşamı tehdit eden durumlarda rituksimab veya siklofosfamid ile glukokortikoid kombinasyonları remisyon sağlamak amacıyla kullanılırken, remisyon sonrası nüksleri önlemek için azatioprin veya metotreksat gibi daha az toksik ajanlarla idame tedavisine geçilir. Erken tanı ve doğru immünsüpresif tedavi stratejileri, hastaların yaşam süresini belirgin şekilde artırır.
This article comprehensively examines antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), including Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA). These complex immune-mediated disorders affecting small vessels lead to severe damage, such as focal necrosis and necrotizing vasculitis, in vital organs including the kidneys, lungs, skin, and ear-nose-throat. Typically presenting with non-specific symptoms like fatigue, fever, and weight loss, these diseases can cause irreversible organ dysfunction or mortality if diagnosis is delayed. ANCA testing, tissue biopsies, and imaging methods like computed tomography play a critical role in the diagnostic process. Therapeutic management consists of two essential phases, induction and maintenance, determined by disease severity. In life-threatening cases, combinations of rituximab or cyclophosphamide with glucocorticoids are utilized to achieve remission, whereas less toxic agents like azathioprine or methotrexate are introduced for maintenance to prevent relapses post-remission. Early diagnosis and accurate immunosuppressive treatment strategies significantly enhance patient survival rates.
Referanslar
Kitching AR, Anders HJ, Basu N, et al. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020; 6: 71.
Liu LJ, Chen M, Yu F, et al. Evaluation of a new algorithm in classification of systemic vasculitis. Rheumatology (Oxford). 2008; 47: 708.
Watts RA, Scott DG, Jayne DR, et al. Renal vasculitis in Japan and the UK--are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant. 2008; 23: 3928.
Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997; 337: 1512.
Falk RJ, Merkel PA, King TE. Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis. In: Up To Date vasculit Medicine [online]. Available from www.uptodate.com [Acessed 5 January 2022].
Merkel PA. Overview of and approach to the vasculitides in adults. In: Up To Date vasculit Medicine [online]. Available from www.uptodate.com [Acessed 30 March 2021].
Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013; 65: 1.
Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994; 37: 187.
Stone JH, Wegener's Granulomatosis Etanercept Trial Research Group. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum. 2003; 48: 2299.
Falk RJ, Nachman PH. Pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis. In: Up To Date vasculit Medicine [online]. Available from www.uptodate.com [acessed 21 October 2020].
Falk RJ, Hogan S, Carey TS, Jennette JC. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann Intern Med. 1990; 113: 656.
Jayne D. The diagnosis of vasculitis. Best Pract Res Clin Rheumatol. 2009; 23: 445.
Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med. 2004; 117: 39.
Gómez-Puerta JA, Hernández-Rodríguez J, López-Soto A, et al. Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease. Chest. 2009; 136: 1101.
Solans-Laqué R, Bosch-Gil J, Canela M, et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. Lupus. 2008; 17: 832.
Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992; 116: 488.
Savage CO, Winearls CG, Evans DJ, et al. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med. 1985; 56: 467.
Micheletti RG, Chiesa Fuxench Z, Craven A, et al. Cutaneous Manifestations of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2020; 72: 1741.
Daoud MS, Gibson LE, DeRemee RA, et al. Cutaneous Wegener's granulomatosis: clinical, histopathologic, and immunopathologic features of thirty patients. J Am Acad Dermatol. 1994; 31: 605.
Harper SL, Letko E, Samson CM, et al. Wegener's granulomatosis: the relationship between ocular and systemic disease. J Rheumatol. 2001; 28: 1025.
Garovic VD, Clarke BL, Chilson TS, et al. Diabetes insipidus and anterior pituitary insufficiency as presenting features of Wegener's granulomatosis. Am J Kidney Dis. 2001; 37: E5.
Czarnecki EJ, Spickler EM. MR demonstration of Wegener granulomatosis of the infundibulum, a cause of diabetes insipidus. Am J Neuroradiol. 1995; 16: 968.
Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. 2000; 43: 1021.
Cannady SB, Batra PS, Koening C, et al. Sinonasal Wegener granulomatosis: a single-institution experience with 120 cases. Laryngoscope. 2009; 119: 757.
Bossuyt X, Cohen Tervaert JW, Arimura Y, et al. Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol. 2017; 13: 683.
Falk RJ, Jennette JC. ANCA small-vessel vasculitis. J Am Soc Nephrol. 1997; 8: 314.
Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int. 1998; 53: 743.
Roth AJ, Ooi JD, Hess JJ, et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest. 2013; 123: 1773.
Cordier JF, Valeyre D, Guillevin L, et al. Pulmonary Wegener's granulomatosis. A clinical and imaging study of 77 cases. Chest. 1990; 97: 906.
Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983; 98: 76.
Haas M, Eustace JA. Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases. Kidney Int. 2004; 65: 2145.
Niles JL, Pan GL, Collins AB, et al. Antigen-specific radioimmunoassays for anti-neutrophil cytoplasmic antibodies in the diagnosis of rapidly progressive glomerulonephritis. J Am Soc Nephrol. 1991; 2: 27.
Kitching AR, Hutchinson P, Atkins RC, et al. The role of flow cytometric ANCA detection in screening for acute pauci-immune crescentic glomerulonephritis. Nephrol Dial Transplant. 2004; 19: 365.
Hauer HA, Bajema IM, Van Houwelingen HC, et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int. 2002; 62: 1732.
de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol. 2006; 17: 2264.
Hauer HA, Bajema IM, van Houwelingen HC, et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int. 2002; 61: 80.
Woodworth TG, Abuelo JG, Austin HA 3rd, et al. Severe glomerulonephritis with late emergence of classic Wegener's granulomatosis. Report of 4 cases and review of the literature. Medicine (Baltimore). 1987; 66: 181.
Merkel PA, Kaplan AA, Falk RJ. Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy. In: Up To Date vasculit Medicine [online]. Available from www.uptodate.com. [Acessed 5 January 2022].
Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum. 2001; 44: 912.
Nachman PH, Hogan SL, Jennette JC, et al. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996; 7: 33.
Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken). 2021; 73: 1088.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021; 100: S1.
Güngör Ö, Öztürk S, Ulu S ve ark. KDIGO 2021 glomerüler hastalıkların yönetı̇mı̇ ı̇çı̇n klı̇nı̇k uygulama kılavuzu: Tavsiye kararları ile pratik uygulama önerilerinin özeti (Türkçe) 2022 (online) (https://nefroloji.org.tr/uploads/pdf/KDIGO-TND.pdf adresinden ulaşılmıştır).
Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 2021; 100: 753.
Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010; 363: 221.
de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009; 150: 670.
Nowack R, Göbel U, Klooker P, et al. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol. 1999; 10: 1965.
Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum. 2004; 51: 278.
Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med. 2021; 384: 599.
Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012; 64: 3760.
Charles P, Perrodeau É, Samson M, et al. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial. Ann Intern Med. 2020; 173: 179.
Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005; 352: 351.
Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003; 349: 36.
Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum. 2000; 43: 1836.
Sneller MC, Hoffman GS, Talar-Williams C, et al. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum. 1995; 38: 608.
McGregor JG, Negrete-Lopez R, Poulton CJ, et al. Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function. Nephrol Dial Transplant. 2015; 30 Suppl 1: i171.
Niles J. Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis. Clin Exp Immunol. 2011; 164 Suppl 1: 27.
Rhee RL, Hogan SL, Poulton CJ, et al. Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease. Arthritis Rheumatol. 2016; 68: 1711.
Wallace ZS, Lu N, Miloslavsky E, et al. Nationwide Trends in Hospitalizations and In-Hospital Mortality in Granulomatosis With Polyangiitis (Wegener's). Arthritis Care Res (Hoboken). 2017; 69: 915.
Lionaki S, Hogan SL, Jennette CE, et al. The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int. 2009; 76: 644.
Robson J, Doll H, Suppiah R, et al. Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015; 74: 177.
Slot MC, Tervaert JW, Franssen CF, et al. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int. 2003; 63: 670.
de Joode AA, Sanders JS, Stegeman CA. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol. 2013; 8: 1709.
Thet Z, Lam AK, Ranganathan D, et al. Cancer risks along the disease trajectory in antineutrophil cytoplasmic antibody associated vasculitis. Clin Rheumatol. 2020; 39: 2501.
Rahmattulla C, Berden AE, Wakker SC, et al. Incidence of Malignancies in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Diagnosed Between 1991 and 2013. Arthritis Rheumatol. 2015; 67: 3270.
Shang W, Ning Y, Xu X, et al. Incidence of Cancer in ANCA-Associated Vasculitis: A Meta-Analysis of Observational Studies. PLoS One. 2015; 10: e0126016.
Mohammad AJ, Segelmark M, Smith R, et al. Severe Infection in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. J Rheumatol. 2017; 44: 1468.
Charlier C, Henegar C, Launay O, et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis. 2009; 68: 658.
Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med. 2005; 143: 621.
Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951; 27: 277.
Churg A. Pulmonary angiitis and granulomatosis revisited. Hum Pathol. 1983; 14: 868.
Sinico RA, Bottero P. Churg-Strauss angiitis. Best Pract Res Clin Rheumatol. 2009; 23: 355.
Talmadge E King TE. Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). In: Up To Date vasculit Medicine [online]. Available from www.uptodate.com [Accessed Jun 23, 2020].
King TE. Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). In: Up To Date vasculit Medicine [online]. Available from www.uptodate.com [Accessed 31 Jan 31 2022].
Sinico RA, Di Toma L, Maggiore U, et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis. 2006; 47: 770.
Clutterbuck EJ, Evans DJ, Pusey CD. Renal involvement in Churg-Strauss syndrome. Nephrol Dial Transplant. 1990; 5: 161.
Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999; 78: 26.
Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013; 65: 270.
Cottin V, Bel E, Bottero P, et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmun Rev. 2017; 16: 1.
Cottin V, Khouatra C, Dubost R, et al. Persistent airflow obstruction in asthma of patients with Churg-Strauss syndrome and long-term follow-up. Allergy. 2009; 64: 589.
Chumbley LC, Harrison EG Jr, DeRemee RA. Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clin Proc. 1977; 52: 477.
Bacciu A, Buzio C, Giordano D, et al. Nasal polyposis in Churg-Strauss syndrome. Laryngoscope. 2008; 118: 325.
Schwartz RA, Churg J. Churg-Strauss syndrome. Br J Dermatol. 1992; 127: 199.
Bridges C, Shenk MER, Martin K, et al. Cutaneous manifestations of childhood Eosinophilic Granulomatosis with Polyangiitis (cEGPA): A case-based review. Pediatr Dermatol. 2020; 37: 604.
Neumann T, Manger B, Schmid M, et al. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore). 2009; 88: 236.
Corradi D, Maestri R, Facchetti F. Postpartum Churg-Strauss syndrome with severe cardiac involvement: description of a case and review of the literature. Clin Rheumatol. 2009; 28: 739.
Dennert RM, van Paassen P, Schalla S, et al. Cardiac involvement in Churg-Strauss syndrome. Arthritis Rheum. 2010; 62: 627.
Moosig F, Bremer JP, Hellmich B, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 2013; 72: 1011.
Della Rossa A, Baldini C, Tavoni A, et al. Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre. Rheumatology (Oxford). 2002; 41: 1286.
Solans R, Bosch JA, Pérez-Bocanegra C, et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology (Oxford). 2001; 40: 763.
Wolf J, Bergner R, Mutallib S, et al. Neurologic complications of Churg-Strauss syndrome--a prospective monocentric study. Eur J Neurol. 2010; 17: 582.
Kronbichler A, Shin JI, Lee KH, et al. Clinical associations of renal involvement in ANCA-associated vasculitis. Autoimmun Rev. 2020; 19: 102495.
Lanham JG, Elkon KB, Pusey CD, et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore). 1984; 63: 65.
Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet. 2003; 361: 587.
Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990; 33: 1094.
Sablé-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005; 143: 632.
Nathani N, Little MA, Kunst H, et al. Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective. Thorax. 2008; 63: 883.
Choi YH, Im JG, Han BK, et al. Thoracic manifestation of Churg-Strauss syndrome: radiologic and clinical findings. Chest. 2000; 117: 117.
Erzurum SC, Underwood GA, Hamilos DL, et al. Pleural effusion in Churg-Strauss syndrome. Chest. 1989; 95: 1357.
Szczeklik W, Sokołowska B, Mastalerz L, et al. Pulmonary findings in Churg-Strauss syndrome in chest X-rays and high resolution computed tomography at the time of initial diagnosis. Clin Rheumatol. 2010; 29: 1127.
Worthy SA, Müller NL, Hansell DM, et al. Churg-Strauss syndrome: the spectrum of pulmonary CT findings in 17 patients. Am J Roentgenol. 1998; 170: 297.
King TE. Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). In: Up To Date vasculit Medicine [online]. Available from www.uptodate.com [Accessed October 04 2021].
Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015; 26: 545.
Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol. 2007; 19: 25.
Bosch X, Guilabert A, Espinosa G, et al. Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA. 2007; 298: 655.10
Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996; 75:17. 5
Samson M, Puéchal X, Devilliers H, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun. 2013; 43: 60.
De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005; 52: 2461.
Gayraud M, Guillevin L, Cohen P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol. 1997; 36: 1290.
Ribi C, Cohen P, Pagnoux C, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. 2008; 58: 586.
Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med. 1998; 129: 370.
